A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician�s Choice of Immune Checkpoint Inhibitor Compared with Docetaxel in Patients with Non-Small-Cell Lung Cancer after First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance (VIRO-25 Study) - Olvi-Vec- NSCLC-025